



Date: August 4, 2023

To,

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 543434	National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051 NSE Symbol: SUPRIYA
---	---

Dear Sir/Madam,

Subject: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing Press Release on the Financial Results of the Company for the quarter ended June 30, 2023.

Request you to kindly take the same on record.

Thanking you,

For Supriya Lifescience Limited

Shweta Singh
Company Secretary & Compliance Officer
Membership No.: A44973

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com

Press release for immediate distribution



Supriya Lifescience Ltd reports Rs 134.9 Crore revenue in Q1FY24, up 30% YoY Reports PAT of Rs 28.51 Crore in Q1FY24, up by 12.9% YoY

Mumbai, August 3, 2023: Supriya Lifescience Ltd, a prominent Mumbai-based company specializing in active pharmaceutical ingredients (API), has declared its results for the quarter ended 30th June 2023, for the fiscal year 2023-24.

Key financial highlights of Q1FY24:

- Total revenue for Q1FY24 reported Rs 134.9 Cr in quarter ended June 30, 2023, as compared to Rs 103.7 Cr reported in similar period YoY
- Total PAT for Q1FY23 reported Rs 28.51 Cr in quarter ended June 30, 2023, as compared to Rs 25.25 Cr in similar period YoY
- Reported PAT margin of 22%
- Reported Gross profit of 64%
- EBITDA reported Rs 44.49 Cr in quarter ended June 30, 2023, as compared to EBITDA of Rs 31.25 Cr in similar quarter YoY
- Healthy EBITDA margin of 34% reported in this quarter
- Asian market contributed over 40% of the business, whereas Europe contributed 35%

Mr. Satish Wagh, Chairman and Managing Director, Supriya Lifescience Ltd, commenting on their results said, “The company has been resilient to the global economic conditions and have delivered a strong comeback. Our strategic business initiatives of deeper penetration in existing markets and tapping new markets, backed by our world class R&D capabilities, have been the key growth drivers for our business. The demand from regulated markets like Europe, North America and Latin America have surged and coming back to normalcy.”

“Our operational efficiency to deliver to the global demand of APIs, customer centricity, consistent and sustainable growth of business and prudent capital allocation strategy is working well for us. As part of our product excellence, the company will constantly invest in R&D capabilities to continuously build new products in new therapeutic areas keeping in mind our existing portfolio of API’s.”

Recently, Supriya Lifescience Ltd, announces its collaboration with **Plasma Nutrition, Inc**, a renowned United States-based company known for innovative consumer products located at Delaware. The strategic partnership involves an exclusive technology licensing agreement, granting Supriya Lifescience Ltd the sole rights for manufacturing and marketing Ingredient Optimized Protein (*ioProtein*) in India.

Disclaimer Statements in this “Document” describing the Company’s objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be “forward looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

About Supriya Lifescience Ltd:

Established in the year 1987, Supriya Lifescience Ltd. is a global leading manufacturer of Active pharmaceutical Ingredients. Our state-of-the-art facility is certified by USFDA, EDQM, EUGMP, NMPA & Health Canada. The facility is located in Khed, District Ratnagiri and headquartered in Mumbai, India.

Backed by strong R&D, 14 active USDMFs, 8 active CEPs & Worldwide compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA). Core business is driven by Ethical values and EHS standards. The company’s focus is to develop APIs and Intermediates for both Innovators, Generic companies and we also partner exclusively as CMO.

For More Details:

Krishna Raghunathan	Abhishek Chawande
Supriya Lifescience Ltd	Dentsu Creative PR
Mob: +91-9963027693	Mob: +91-9664516774
e-mail: cfo@supriyalifescience.com	e-mail: abhishek.chawande@dentsu.com